Use of long-acting risperidone in the treatment of bipolar patients [1]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 5, 2006, Pages 530-531

  Savas, Haluk A ^a   Yumru, Mehmet ^a   Özen, Murat Eren ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

BECH-RAFAELSEN MANIA SCALE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; LETTER; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME;

EID: 33748741256     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000231609.91144.00     Document Type: Letter

References (11)

1. Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005;860:1-10.
2. Yatham LN. Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol. 2003;23:9-14.
3. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl). 2003;166:315-332.
4. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:1263-1271.
5. Yatham LN, Binder C, Riccardelli R, et al. RIS-CAN 25 Study Group: risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol. 2003;18:227-235.
6. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77:215-227.
7. Montgomery DB. European College of Neuropsychopharmacology ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol. 2001;11:79-88.
8. Jensen HV, Plenge P, Mellerup ET, et al. Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatr Scand. 1995;92:69-74.
9. Sajatovic M, Madhusoodanan S, Fuller MA, et al. Risperidone for bipolar disorders. Expert Rev Neurother. 2005;5:177-187.
10. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D. 2005;6:129-137.
11. Lasser RA, Bossie CA, Gharabawi GM, et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord. 2004;83:263-275.